many patiently awaiting published report recently concluded kennedy disease bvs trial nih two attendees provided following information trial actual paper published i provide link dr kenneth fischbeck nih gave report trial kda conference san diego last week stated modest positive results meet expectations part may conducted trial weeks nature drug effect would suggest slowly increasing benefits extended time frame compound intended improve insulin sensitivity people kd boost anabolic effects insulin igf unfortunately also stimulated immune response patients taking producing anti bodies attacked drug also attacked person insulin igf fortunately affected discontinuing drug immune response faded novartis aborted trial plans terminated investigation compound following quote dr fischbeck disappointed novartis agent effective optimistic results trial help developing treatment really works kennedy disease study gave information muscle imaging clinical outcome measures improve design future trials helped set network trial sites allow clinical studies done efficiently also gave indication effect muscle size drugs targeting pathway might effective